V

Verona Pharma plc
D

VRNA

92.665
USD
0.42
(0.45%)
مغلق
حجم التداول
0
الربح لكل سهم
-0
العائد الربحي
-
P/E
-46
حجم السوق
7,888,757,058
أصول ذات صلة
AZN
AZN
-0.875
(-1.18%)
73.550 USD
BNTX
BNTX
-0.350
(-0.33%)
106.360 USD
GSK
GSK
-0.330
(-0.81%)
40.510 USD
JNJ
JNJ
-1.810
(-1.15%)
155.280 USD
MRK
MRK
-0.760
(-0.93%)
80.980 USD
MRNA
MRNA
-0.650
(-2.44%)
26.030 USD
N
NVAX
0.10500
(1.52%)
7.03500 USD
PFE
PFE
-0.130
(-0.53%)
24.405 USD
REGN
REGN
-6.74
(-1.27%)
522.65 USD
SNY
SNY
-0.240
(-0.48%)
49.440 USD
المزيد
الأخبار المقالات

العنوان: Verona Pharma plc

القطاع: Healthcare
الصناعة: Biotechnology
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.